Multiple sclerosis: Fingolimod failure in progressive MS INFORMS future trials

[1]  Ludwig Kappos,et al.  Oral fingolimod in primary progressive multiple sclerosis (INFORMS): a phase 3, randomised, double-blind, placebo-controlled trial , 2016, The Lancet.

[2]  D. Ontaneda,et al.  Clinical trials in progressive multiple sclerosis: lessons learned and future perspectives , 2015, The Lancet Neurology.

[3]  B. Trapp,et al.  Pathological mechanisms in progressive multiple sclerosis , 2015, The Lancet Neurology.

[4]  Ludwig Kappos,et al.  Safety and efficacy of fingolimod in patients with relapsing-remitting multiple sclerosis (FREEDOMS II): a double-blind, randomised, placebo-controlled, phase 3 trial , 2014, The Lancet Neurology.

[5]  Jeffrey A. Cohen,et al.  Mechanisms of fingolimod's efficacy and adverse effects in multiple sclerosis , 2011, Annals of neurology.

[6]  Ludwig Kappos,et al.  Oral fingolimod or intramuscular interferon for relapsing multiple sclerosis. , 2010, The New England journal of medicine.

[7]  P. Calabresi,et al.  Rituximab in patients with primary progressive multiple sclerosis: Results of a randomized double‐blind placebo‐controlled multicenter trial , 2009, Annals of neurology.

[8]  P. Narayana,et al.  Glatiramer acetate in primary progressive multiple sclerosis: Results of a multinational, multicenter, double‐blind, placebo‐controlled trial , 2007, Annals of neurology.

[9]  Ludwig Kappos,et al.  Oral fingolimod (FTY720) for relapsing multiple sclerosis. , 2006, The New England journal of medicine.

[10]  D. Arnold,et al.  Efficacy and safety of ocrelizumab in primary progressive multiple sclerosis - results of the placebo-controlled, double-blind, Phase III ORATORIO study , 2015 .